Rosa M. Lorente-Ramos MD, PhD, Presenter: Nothing to Disclose

Javier Azpeitia Arman MD, Abstract Co-Author: Nothing to Disclose

Teresa Rivera Garcia, Abstract Co-Author: Nothing to Disclose

Isabel Casado Farinas, Abstract Co-Author: Nothing to Disclose

Miguel Angel Lara Alvarez, Abstract Co-Author: Nothing to Disclose

1) Understand the basic pathological changes in advanced breast cancer and lymph nodes after neoadjuvant chemotherapy. 2) Correlate pathologic changes with imaging (MR, mammograms, US). 3) Learn an approach to the assessment of the postneoadjuvancy breast.

We present: 1-Pathologic description of the residual lesion at surgery with comparison with the pretreatment tumor biopsy. -Macroscopy. Size of tumor bed, and residual tumor. -Microscopy. Presence and size of infiltrating carcinoma, number of foci,Histologic Appearance and Tumor Grade, lymphovascular involvement, presence of DCIS, Miller Payne classification of response, margins, 2-Imaging findings in breasts of patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC): mammograms, US and MR, dynamic contrast-enhanced and diffusion weighted imaging. -Tumor size, - Change in size, -Type of response: complete response, mass shrinkage, fragmentation. 3- Pathologic response in lymph nodes. -Number of nodes -Number of affected nodes -Extranodal involvement -Miller-payne system. Presence of metastases in nodes and postchemocheraphy changes 4- Imaging assessment of axillary lymph nodes. -Suspicious nodes -Extranodal involvement  

http://abstract.rsna.org/uploads/2014/14004114/14004114_fli2.pdf

Lorente-Ramos, R, Azpeitia Arman, J, Rivera Garcia, T, Casado Farinas, I, Lara Alvarez, M, Breast and Axillary Lymph Node Response to Neoadjuvant Chemotherapy: How Radiologic-Pathologic Correlation Informs Interpretation.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004114.html